Sean K
Moderator
- Joined
- 21 April 2006
- Posts
- 22,324
- Reactions
- 11,619
The author is an intern, still at university.
His LinkIn profile summary:
He looks at least 19.
The author is an intern, still at university.http://seekingalpha.com/article/113...hort-squeeze?source=email_rt_article_readmore
An Interview With Unilife's CEO: A Long-Term Opportunity And A Looming Short Squeeze
January 25, 2013 | about: UNIS
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
By Ivan Deryugin
I currently attend Vanderbilt University, where I am double majoring in economics & political science, with a minor in corporate strategy. I have been trading equities and options for the past 5 years, and founded Helix Investment Management in July 2011 to pay for my educational expenses, as well as manage my family's assets. I publish equity research for Seeking Alpha and PropThink, and am currently an asset management intern at Mastrapasqua Asset Management, where I cover the life science and biotechnology sectors.
Do you have aproblem with a uni student working their way through college In a field related to their studies
Others have responded to his article. Scroll down and you find a critical analysis of AS and his not so brilliant career.If you do you can always use the hyperlink at the bottom of the article to submit your own
January 31, 2013
Dear Fellow Shareholders
We look forward to finalizing negotiations with multiple pharmaceutical companies for a series of contracts throughout 2013.
Due to the strong relationships we have established with more than 40 new and prospective customers, including many of the 20 largest pharmaceutical companies in the world, we believe that these prospective agreements in 2013 will simply pave the way for even greater things to come. Most of these pharmaceutical companies have advised that they are targeting our devices for use with multiple approved and late-stage pipeline drugs. As each of these target drugs reaches peak annual commercial sales in future years, we expect to have a series of long-term contracts that will collectively generate recurring, potential revenues in excess of $1 billion a year with attractive operating margins. Our commercial pipeline continues to diversify beyond these active programs, with additional evaluations commencing with ten prospective new customers this month alone.
Letter to shareholders today.
Again sprewking $1b in sales in the not too distant future.
From $10m losses a quarter to $1b in revenue in the flashes of flashes.
This is going to end in tears.
Can't name the pharma companies though...
I think we've read these promises before. Like back when it was an Australian based company but had to leave.
Stick, I'm not sure what this is showing?
http://carpedmstocks.blogspot.com.au/2013/02/unis-jpmorgan-adds-boatload.html
$UNIS - JPMorgan Adds a Boatload
JP Morgan Chase & Co. just filed a form schedule 13-d http://www.sec.gov/Archives/edgar/data/19617/000001961713000178/Unlifecorp.htm for its holdings in $UNIS. They have added an additional 1 million + shares to their holdings and now hold 8.8% of the company's stock. Other funds continue to add and there are a few newcomers as well. While the Nasdaq site hasn't updated to show this information, another major fund made an initial purchase of over 600,000 shares. This just bodes the question, at what point will the shorts be shorting shares that they have already shorted. Its possible this is already happening. Much of their enthusiasm is probably predicated on the logic that the company will report a similar quarter as the previous ones and that they'll be able to get weak hands to sell out with some pressure. The selling pressure of late has been met with equally strong buying pressure. The shares trading on the Nasdaq have been in a very narrow range. For the sake of simplicity if we assume that 42 million shares are available for trading on Nasdaq. Out of that 42 million shares, I estimate that 32 million are held by funds leaving 10 million shares left for the hoi polloi. Shorters have already sold over 10 million shares, which means that should there be any kind of news that generates real excitement, ie, revenue generation or supply contracts, they will be competing for an ever shrinking number of shares. Many will continue to short all the way up hoping that the stock will fall after the excitement dies down, but with so few shares truly available, they will have no place to go but back into the market. We know that the PR machine is primed and ready to go once the company is ready to announce some big news. The countdown clock may have already started.
A 15 year agreement for a drug going through clinical development.Unilife Signs Long-Term Customization and Commercial Supply Agreement for EZMix Dual Chamber Syringe
***
15-Year Contract Expected to Generate up to $110 Million, with Revenue Starting Immediately Unilife to Receive a Royalty of Net Drug Sales in Exchange for Exclusivity Rights
York, PA (April 9, 2013) Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS, ASX: UNS) today announced the signing of a Customization and Commercial Supply Agreement with a U.S. pharmaceutical company (the “Customer”) for the EZMixTM dual-chamber syringe.
Unilife will supply the Customer with a customized device from its EZMix platform of dual-chamber delivery systems (“EZMix” or the “device”) for use with a lyophilized drug (the “Drug”) that requires mixing at the time of injection. The Drug, which is a proprietary version of an approved therapy, is entering late-stage clinical development with the Customer planning an accelerated pathway to U.S. regulatory approval.
Unilife expects to generate up to $110 million in revenue during the 15-year agreement based upon a customization and production scale-up program, commercial device sales and a royalty of net drug sales. Unilife will immediately begin to generate revenues under the program.
The Customer will pay Unilife approximately $3 million over a 12 to 24-month period for the customization and supply of prefilled EZMix devices for scheduled activities including human clinical drug trials and compatibility testing. Unilife will receive an additional $3 million from the Customer to fund the production scale-up of high-volume assembly equipment to manufacture the customized device at commercial volumes.
I am therefore pleased to advise that we have agreed to preliminary terms with a leading U.S. life science financing firm for a debt funding program that we expect to finalize shortly. Combined with the anticipated revenue to be generated from new and existing customer agreements, we expect this medium-term debt program to strengthen our balance sheet, reduce the need for a secondary stock offering and thereby minimize potential dilution to existing shareholders.
“Having long said that 2013 would be the inflection point for our business, I am pleased to have turned the corner. We are now entering a period of hyper-growth, and expect to generate accelerating, recurring revenue from an expanding base of customers,” stated Mr. Alan Shortall, CEO of Unilife.
“Last month, we announced the first in a series of agreements with immediate revenue. This 15-year customization and supply contact for the EZMix dual-chamber syringe is with a U.S. based pharmaceutical company that we expect will generate up to $110 million in cumulative revenue.
“We are getting ready to announce our first major long-term supply contract for the Unifill syringe. This is a significant multi-year commercial supply contract with a major pharmaceutical customer that generates revenue immediately. Negotiations for this agreement are complete and all terms have been agreed upon, with the execution copy now being routed for signature by both parties. I expect this agreement will establish Unilife as one of the leading suppliers of prefilled syringes in our industry.
“With so many transformational agreements generating immediate revenue, we have no intention of doing any secondary stock offering that would cause significant dilution to existing shareholders.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?